Kezar Life Sciences, Inc.

Cash, cash equivalents and marketable securities were $157.5 million as of June 30, 2020, versus $78.2 million at December 31, 2019. Q2 2020 R&D expense was $7.1 million, up from $6.9 million a year ago; G&A expense was $2.7 million, up from $2.4 million. Net loss was $9.5 million, or $0.22 per basic and diluted share, versus a net loss of $8.7 million, or $0.46 per basic and diluted share, in Q2 2019. Management said the cash runway lasts through 2023 based on current plans. For guidance, KZR-616 Phase 1b was expected to finish in early 2021, interim MISSION Phase 2 data were expected in late 2021, PRESIDIO completion moved to mid-2022, and KZR-261 IND filing was planned for Q1 2021.

John Fowler framed the quarter around confidence in Kezar’s two platforms: KZR-616 for autoimmune disease and KZR-261 for cancer. He emphasized that the company is becoming more focused after reviewing the Phase 1b lupus data and COVID’s impact on enrollment, and he described the KZR-616 findings as increasing optimism about the drug’s potential to be a “game-changer.” His tone was upbeat and strategic, with repeated emphasis on broad therapeutic potential, a strong balance sheet, and the ability to keep advancing both programs.

Marc Belsky said Kezar ended the quarter with $157.5 million in cash, cash equivalents and marketable securities, boosted by February and June public offerings, net of operating cash burn. He reported Q2 R&D expense of $7.1 million, up $200,000 year over year, mainly from the protein secretion preclinical program, and G&A expense of $2.7 million, up $300,000, mainly from personnel and stock-based compensation. He also noted the net loss of $9.5 million, or $0.22 per share, and said the current cash position supports operations through 2023.

Analysts focused on why Cohort 2c was better tolerated, and management pointed to three factors: the shift to a lyophilized formulation, step-up dosing, and supportive pre-dose measures such as oral hydration and non-sedating antihistamines. Questions also centered on the MISSION Phase 2 redesign; management confirmed it is now a single-arm, 60 mg weekly study with 20 patients and a 50% UPCR reduction endpoint, dropping the earlier randomized multi-dose design. Analysts pressed on COVID impacts, and Kezar said enrollment delays pushed PRESIDIO completion to mid-2022 and that it is looking to expand its clinical footprint; on MARINA, management said no patients had been enrolled and the study was withdrawn to be reworked.